Lawmakers Want Probe of BMS/Celgene Deal’s Effect on Competition, Prices

Drug Industry Daily
A A
Two U.S. Representatives — one a Republican, the other a Democrat — are calling for a government probe into how Bristol-Myers Squibb’s planned $74 billion acquisition of Celgene could affect competition and drug prices.

To View This Article:

Login

Subscribe To Drug Industry Daily